Five Oceans Advisors Increases Stock Position in Eli Lilly and Company (NYSE:LLY)

Five Oceans Advisors increased its position in shares of Eli Lilly and Company (NYSE:LLYGet Rating) by 6.0% during the 2nd quarter, Holdings Channel reports. The firm owned 1,215 shares of the company’s stock after purchasing an additional 69 shares during the quarter. Five Oceans Advisors’ holdings in Eli Lilly and were worth $394,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in LLY. Vanguard Group Inc. boosted its position in Eli Lilly and by 1.8% in the first quarter. Vanguard Group Inc. now owns 70,481,178 shares of the company’s stock worth $20,183,695,000 after purchasing an additional 1,219,424 shares during the last quarter. State Street Corp boosted its holdings in shares of Eli Lilly and by 2.5% in the 4th quarter. State Street Corp now owns 33,929,864 shares of the company’s stock worth $9,372,107,000 after buying an additional 813,983 shares during the last quarter. Capital World Investors grew its position in Eli Lilly and by 17.0% during the first quarter. Capital World Investors now owns 22,358,444 shares of the company’s stock valued at $6,402,838,000 after buying an additional 3,242,548 shares during the period. Capital International Investors increased its holdings in Eli Lilly and by 30.5% during the first quarter. Capital International Investors now owns 8,839,241 shares of the company’s stock worth $2,532,024,000 after buying an additional 2,063,557 shares during the last quarter. Finally, Norges Bank bought a new stake in Eli Lilly and in the fourth quarter worth about $2,213,765,000. 82.45% of the stock is owned by institutional investors.

Eli Lilly and Price Performance

Shares of NYSE LLY traded up $0.90 during mid-day trading on Friday, reaching $311.77. 41,457 shares of the company were exchanged, compared to its average volume of 2,237,822. The stock has a market capitalization of $296.23 billion, a PE ratio of 49.58, a PEG ratio of 1.92 and a beta of 0.38. The company has a quick ratio of 0.85, a current ratio of 1.10 and a debt-to-equity ratio of 1.70. Eli Lilly and Company has a 52 week low of $220.20 and a 52 week high of $335.33. The company’s 50 day moving average price is $314.33 and its 200 day moving average price is $304.45.

Eli Lilly and (NYSE:LLYGet Rating) last posted its quarterly earnings data on Thursday, August 4th. The company reported $1.25 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.86 by ($0.61). The firm had revenue of $6.49 billion during the quarter, compared to analysts’ expectations of $6.85 billion. Eli Lilly and had a return on equity of 85.58% and a net margin of 19.58%. Eli Lilly and’s revenue for the quarter was down 3.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.87 earnings per share. Sell-side analysts forecast that Eli Lilly and Company will post 7.97 earnings per share for the current fiscal year.

Eli Lilly and Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 9th. Stockholders of record on Monday, August 15th were paid a $0.98 dividend. The ex-dividend date was Friday, August 12th. This represents a $3.92 dividend on an annualized basis and a dividend yield of 1.26%. Eli Lilly and’s dividend payout ratio (DPR) is 62.52%.

Insider Activity at Eli Lilly and

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 89,458 shares of the company’s stock in a transaction dated Thursday, July 28th. The shares were sold at an average price of $332.85, for a total transaction of $29,776,095.30. Following the completion of the sale, the insider now directly owns 103,875,441 shares in the company, valued at $34,574,940,536.85. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 89,458 shares of the stock in a transaction on Thursday, July 28th. The shares were sold at an average price of $332.85, for a total transaction of $29,776,095.30. Following the completion of the sale, the insider now owns 103,875,441 shares of the company’s stock, valued at approximately $34,574,940,536.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Alonzo Weems sold 656 shares of the business’s stock in a transaction dated Wednesday, August 10th. The shares were sold at an average price of $304.50, for a total transaction of $199,752.00. Following the completion of the transaction, the senior vice president now owns 8,136 shares in the company, valued at approximately $2,477,412. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 328,125 shares of company stock valued at $108,581,151. Insiders own 0.12% of the company’s stock.

Analyst Upgrades and Downgrades

LLY has been the topic of a number of research reports. JPMorgan Chase & Co. lifted their price target on shares of Eli Lilly and from $340.00 to $355.00 in a report on Wednesday, June 1st. BMO Capital Markets upped their price target on Eli Lilly and from $369.00 to $396.00 and gave the company an “outperform” rating in a research report on Tuesday, September 6th. Barclays lifted their price objective on Eli Lilly and from $333.00 to $355.00 and gave the stock an “overweight” rating in a report on Thursday, July 7th. UBS Group raised shares of Eli Lilly and from a “neutral” rating to a “buy” rating and upped their price objective for the company from $335.00 to $363.00 in a report on Thursday. Finally, Morgan Stanley lifted their target price on shares of Eli Lilly and from $395.00 to $412.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 7th. Three research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $332.19.

Eli Lilly and Profile

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Recommended Stories

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYGet Rating).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.